Found 1 publication.
Displayed publication 1
Expand all publications
Collapse all publications
Show all as text (SweetDB notation)
Show all graphically (SNFG notation)
1. (Article ID: 9217)
Yadav SK, Ir R, Jeewon R, Doble M, Hyde KD, Kaliappan I, Jeyaraman R, Reddi RN, Krishnan J, Li M, Durairajan SSK
A mechanistic review on medicinal mushrooms-derived bioactive compounds: Potential mycotherapy candidates for alleviating neurological disorders
Planta Medica 86(16) (2020)
1161-1175
According to the World Health Organization, neurological and neurodegenerative diseases are highly debilitating and pose the greatest threats to public health. Diseases of the nervous system are caused by a particular pathological process that negatively affects the central and peripheral nervous systems. These diseases also lead to the loss of neuronal cell function, which causes alterations in the nervous system structure, resulting in the degeneration or death of nerve cells throughout the body. This causes problems with movement (ataxia) and mental dysfunction (dementia), both of which are commonly observed symptoms in Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. Medicinal mushrooms are higher fungi with nutraceutical properties and are low in calories and fat. They are also a rich source of nutrients and bioactive compounds such as carbohydrates, proteins, fibers, and vitamins that have been used in the treatment of many ailments. Medicinal mushrooms such as Pleurotus giganteus, Ganoderma lucidium, and Hericium erinaceus are commonly produced worldwide for use as health supplements and medicine. Medicinal mushrooms and their extracts have a large number of bioactive compounds, such as polysaccharide β-glucan, or polysaccharide-protein complexes, like lectins, lactones, terpenoids, alkaloids, antibiotics, and metal-chelating agents. This review will focus on the role of the medicinal properties of different medicinal mushrooms that contain bioactive compounds with a protective effect against neuronal dysfunction. This information will facilitate the development of drugs against neurodegenerative diseases.
medicinal mushrooms, Ganoderma, bioactive compounds, Pleurotus, neurodegenerative diseases, Cyathus, Sarcodon, Hericium, Antrodia, neurological disorder
NCBI PubMed ID: 32663897Publication DOI: 10.1055/a-1177-4834Journal NLM ID: 0066751Publisher: George Thieme
Correspondence: Durairajan SSK
cutn.ac.in>; Li M hkbu.edu.hk>
Institutions: Center of Excellence in Fungal Research, Mae Fah Luang University, Chiang Rai, Thailand, Division of Mycobiology and Neurodegenerative Disease Research, Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Tiruvarur, India, Department of Health Sciences, Faculty of Science, University of Mauritius, Reduit, Mauritius, Department of Biotechnology, Indian Institute of Technology Madras, Chennai, India, Interdisciplinary Institute of Indian System of Medicine, SRM Institute of Science and Technology, Kattankulathur, India, Corrosion and Materials Protection Division, CSIR-Central Electrochemical Research Institute, Karaikudi, India, Department of Organic Chemistry, Weizmann Institute of Science, Rehovot, Israel, Department of Life Sciences, School of Life Sciences, Central University of Tamil Nadu, Tiruvarur, India, Mr. & Mrs. Ko Chi-Ming Centre for Parkinsonʼs Disease Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
The publication contains the following compound(s):
- Compound ID: 20827
|
b-D-Xylp-(1-6)-Subst
Subst = erinacine A aglycon = SMILES CC(C)/C3=C/2\C1=C\C=C(C=O)/C{6}[C@H](O)[C@]1(C)CC[C@@]2(C)CC3 |
Show graphically |
Structure type: monomer
Trivial name: erinacine A
Compound class: glycoside, diterpene glycoside
- Compound ID: 20828
|
b-D-Xylp-(1-6:2-7)-Subst
Subst = erinacine B aglycon = SMILES CC(C)/C3=C/2[C@H]1C/C=C(C=O)\{7}[C@@H](O){6}[C@H](O)[C@]1(C)CC[C@@]2(C)CC3 |
Show graphically |
Structure type: monomer
Trivial name: erinacine B
Compound class: glycoside, diterpene glycoside
- Compound ID: 20829
|
b-D-Xylp-(1-6:2-7)-Subst
Subst = erinacine C aglycon = SMILES CC(C)/C3=C/2[C@H]1C/C=C({15}CO)\{7}[C@@H](O){6}[C@H](O)[C@]1(C)CC[C@@]2(C)CC3 |
Show graphically |
Structure type: monomer
Trivial name: erinacine C
Compound class: glycoside, diterpene glycoside
- Compound ID: 20830
|
b-D-Xylp-(1-6)-Subst9Et
Subst = erinacine D aglycon = SMILES CC(C)/C3=C/2[C@H]1C{9}[C@H](O)/C(C=O)=C\{6}[C@H](O)[C@]1(C)CC[C@@]2(C)CC3 |
Show graphically |
Structure type: monomer
Trivial name: erinacine D
Compound class: glycoside, diterpene glycoside
- Compound ID: 20831
|
b-D-Xylp-(1-6)-Subst
Subst = erinacine H aglycon = SMILES CC(C)/C3=C/2\C1=C\C=C({15}C(=O)O)/C{6}[C@H](O)[C@]1(C)CC[C@@]2(C)CC3 |
Show graphically |
Structure type: monomer
Trivial name: erinacine H
Compound class: glycoside, diterpene glycoside
- Compound ID: 20835
|
b-D-Xylp-(1-6)-Subst15Ac
Subst = erinacine K aglycon = SMILES CC(C)/C3=C/2[C@H]1C{9}C(O)/C({15}CO)=C\{6}[C@H](O)[C@]1(C)CC[C@@]2(C)CC3 |
Show graphically |
Structure type: monomer
Trivial name: erinacine K
Compound class: glycoside, diterpene glycoside
- Compound ID: 20248
Structure type: monomer
Trivial name: uridine, cytidine
Compound class: glycoside, nucleoside
- Compound ID: 19878
Structure type: monomer
Trivial name: adenosine, Adenosine
Compound class: glycoside, flavonoid glycoside, nucleoside
Reference(s) to other database(s): GenDB: EU926976
Expand this publication
Collapse this publication
Total list of publication IDs on all result pages of the current query:
Total list of corresponding CSDB IDs (permanent record IDs):
Execution: <1 sec